Angiogenesis, immunotherapy and biomarkers research in glioblastoma

Speaker: Michael Weller

M. Weller says that in last 5 to 10 years angiogenesis has dominated the research agenda in glioblastoma with bevacizumab being the most prominent agent studied. When there is no success with single agents, clinical trials consider combinations; he describes the safety data of pembrolizumab in combination with bevacizumab in recurrent glioblastoma as presented at the ASCO 2016 Annual Meeting. Furthermore, he discusses biomarkers in glioma, in particular IDH.

Discussion Points

  1. Current research scenario in glioblastoma
  2. Perspective of immunotherapy in glioma treatment; combination with anti-angiogenesis
  3. Highlights from glioblastoma studies presented at ASCO 2016
  4. Biomarker research in glioma: A focus on IDH

Abstract  2010: Safety of pembrolizumab in combination with bevacizumab in recurrent glioblastoma (rGBM).

Abstract  2009: Predicting isocitrate dehydrogenase genotype in malignant glioma with multimodality imaging markers.